{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '6.2.', 'Preparation/Handling/Storage/Accountability', '1. The investigator or designee must confirm appropriate temperature conditions have been', 'maintained during transit for all IP received and any discrepancies are reported and', 'resolved before use of the IP.', '2. Only subjects enrolled in the study may receive IP and only authorized site staff may', 'supply IP. All IP must be stored in a secure, environmentally controlled, and monitored', '(manual or automated) area in accordance with the labeled storage conditions with access', 'limited to the investigator and authorized site staff.', '3. The investigator, institution, or the head of the medical institution (where applicable) is', 'responsible for IP accountability, reconciliation, and record maintenance (ie, receipt,', 'reconciliation, and final disposition records).', '4. Further guidance and information for the final disposition of IP are provided in the', 'Pharmacy Manual.', '6.3.', 'Randomization and Blinding', '6.3.1.', 'Randomization', 'All subjects will be centrally randomized to IP treatment group using an Interactive Response', 'Technology (IRT). Before the study is initiated, directions for use of the system will be provided', 'to the sites.', 'Randomization will be stratified by country, the presence or absence of NP (CRSwNP and', 'CRSsNP), and the presence or absence of comorbid asthma among CRSwNP subjects. Presence', 'of NP is defined by a minimum NPS of 4 out of a maximum score of 8 with a score of at least 2', 'for each nostril. Absence of NP is defined as an absence of NP based on visual examination or an', 'NPS of 0 based on nasal endoscopy. Presence of comorbid asthma is defined as a diagnosis of', 'asthma by a physician according to Global Initiative for Asthma (GINA) guidelines at screening', 'or prior to study entry. The CRSwNP stratum will consist of approximately 64 subjects, and the', 'CRSsNP stratum will consist of approximately 36 subjects.', '6.3.2.', 'Assignment of Investigational Product Bottle Numbers', 'IP will be dispensed at the study visits as summarized in SoA. At the Randomization Visit, the', \"IRT system will assign an IP bottle number based on the subject's randomized treatment group.\", 'For subsequent visits when IP is dispensed, the IRT system will assign new IP bottle numbers', \"based on the subject's randomized treatment group.\", '6.3.3.', 'Unblinding of an Individual Subject', 'The IRT system will be programmed with blind-breaking instructions. In case of a medical', 'emergency, the investigator has the sole responsibility for determining if unblinding of', \"a subject's treatment assignment is warranted. Subject safety must always be the first\", 'consideration in making such a determination. If the investigator decides that unblinding is', 'warranted, the investigator, when possible, should make an effort to contact the Sponsor to', \"discuss unblinding a subject's treatment assignment, unless this could delay emergency medical\", '31', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', \"treatment of the subject. If a subject's treatment assignment is unblinded, the Sponsor must be\", 'notified within 24 hours after breaking the blind. The date and reason that the blind was broken', 'must be recorded in the source documentation and electronic case report form (eCRF).', 'Appropriate personnel at the Sponsor will unblind suspected unexpected serious adverse', 'reactions (SUSARs) for the purpose of regulatory reporting. The Sponsor will submit SUSARs', 'to Regulatory Agencies in blinded or unblinded fashion according to local law. The Sponsor will', 'submit SUSARs to Investigators in a blinded fashion.', 'Designated Sponsor (or designee) personnel will have access to unblinded individual subject', 'treatment assignments for the purposes of study-required activities including management of IP', 'inventory and performance of bioanalytical analysis of PK concentrations.', 'Up to 3 Sponsor individuals not directly involved in the conduct of the study may access', 'unblinded individual subject treatment assignments during the course of the study for the', 'purpose of performing informal analyses to inform further development of GB001. No', 'modifications will be made to the study based on this unblinded access, and there will be no', 'communication of any analyses performed or their results outside of these designated Sponsor', 'individuals. Subjects, investigators and other site personnel, and Sponsor (or designee) personnel', 'who are directly involved in the conduct of the study will remain blinded to treatment', 'assignments until after the completion of the study and the database has been locked.', '6.4.', 'Investigational Product Compliance', 'For additional details refer to Study Reference Manual and/or Pharmacy Manual.', 'IP accountability will be assessed at each visit by counting returned tablets. Deviation(s) from', 'the prescribed dosage regimen will be evaluated per guidelines provided in the Study Reference', 'Manual and the Pharmacy Manual. Subjects who demonstrate poor IP compliance, in the opinion', 'of the Investigator, should be reeducated on the importance of taking their medications.', 'Guidance for Missed Dose(s)', 'If a dose is missed, subjects should be instructed to skip the missed dose and resume dosing', 'at their next scheduled dosing time. For additional details refer to Study Reference Manual and', 'Pharmacy Manual.', '32', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}